Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 3, 2010, Pages

  Skoner, David ^a   Gentile, Deborah ^a   Bush, Robert ^b   Fasano, Mary Beth ^c   McLaughlin, Anne ^d   Esch, Robert E ^e  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d Welborn Clinic Research Center   (United States)

^e Greer Laboratories Inc   (United States)

Author keywords

Allergic rhinoconjunctivitis; maximum tolerable dose; medication score; subcutaneous immunotherapy; sublingual immunotherapy; symptom score

Indexed keywords

ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; PLACEBO; POLLEN EXTRACT; RAGWEED POLLEN EXTRACT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BLOOD CLOT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EYE SWELLING; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; NAUSEA; PRIORITY JOURNAL; RAGWEED POLLEN; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOCONJUNCTIVITIS; SIDE EFFECT; SPONTANEOUS ABORTION; STOMACH DISCOMFORT; SWOLLEN UVULA; TREATMENT DURATION; TREATMENT WITHDRAWAL;

EID: 77649274006     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.12.931     Document Type: Article

References (35)

1. Finegold I. Allergen immunotherapy: present and future. Allergy Asthma Proc 28 (2007) 44-49
2. Leatherman B.D., Owen S., Parker M., Chadwick S., Fornadley J.A., Colson D., et al. Sublingual immunotherapy: past, present, paradigm for the future? a review of the literature. Otolaryngol Head Neck Surg 136 suppl 3 (2007) S1-S20
3. Canonica G., and Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 111 (2003) 437-448
4. Cox L.S., Linnemann D.L., Nolte H., Weldon D., Finegold I., and Nelson H.S. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 117 (2006) 1021-1035
5. Esch R.E. Sublingual immunotherapy. Curr Opin Otolaryngol Head Neck Surg 16 (2008) 260-264
6. André C., Perrin-Fayolle M., Grosclaude M., Couturier P., Basset D., Cornillon J., et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis: evidence for a dose-response relationship. Int Arch Allergy Immunol 131 (2003) 111-118
7. Bowen T., Greenbaum J., Charbonneau Y., Hebert J., Filderman R., Sussman G., et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 93 (2004) 425-430
8. Calamita Z., Saconato H., Pelá A.B., and Atallah A.N. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 61 (2006) 1162-1172
9. Garcia-Marcos L., Lucas Moreno J.M., and Garde J.G. Sublingual specific immunotherapy: state of the art. Inflamm Allergy Drug Targets 6 (2007) 117-126
10. Wilson D.R., Torres Lima M., and Durham S.R. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2 (2003) CD002893
11. Penagos M., Compalati E., Tarantini F., Baena-Cagnani R., Huerta J., Passalacqua G., et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double blind trials. Ann Allergy Asthma Immunol 97 (2006) 141-148
12. Penagos M., Passalacqua G., Compalati E., Baena-Cagnani C.E., Orozco S., Pedroza A., et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 133 (2008) 599-609
13. Cox L. Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations. Curr Allergy Asthma Rep 7 (2007) 410-420
14. Malling H- J. Sublingual immunotherapy: efficacy-methodology and outcome of clinical trials. Allergy 61 suppl 81 (2006) 24-28
15. Didier A., Malling H.J., Worm M., Horrak F., Jäger S., Montagut A., et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 120 (2007) 1338-1345
16. Esch R.E., Bush R.K., Peden D., and Lockey R.F. Safety of SLIT with standardized allergenic extracts: phase 1 safety and dosing trials. Ann Allergy Asthma Immuol 100 (2008) 475-481
17. Rajakulasingam K. Nasal provocation testing. In: Adkinson Jr. N.F., Yunginger J.W., Busse W.W., Bochner B.S., Holgate S.T., and Simons F.E.R. (Eds). Middleton's allergy: principles and practice. 6th ed. (2003), Mosby, Philadelphia (PA) 644-655
18. Clark J., and Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy 62 (2007) 1023-1028
19. Rossi R.E., Monasterolo G., Coco G., Silvestro L., and Operti D. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine 25 (2007) 957-964
20. Pfarr O., and Klimek L. Efficacy and safety of specific immunotherapy with high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 100 (2008) 256-263
21. Moingeon P., Batard T., Fadel R., Frati F., Sieber J., and Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61 (2006) 151-165
22. Francis J.N., James L.K., Paraskevopoulos G., Wong C., Calderon M.A., Durham S.R., et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 121 (2008) 1120-1125
23. Nouri-Aria K.T., Wachholz P.A., Francis J.N., Jacobson M.R., Walker S.M., Wilcock L.K., et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 172 (2004) 3252-3259
24. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., and Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006) 802-809
25. Subiza J., Feliu A., Subiza J.L., Uhlig J., and Fernandez-Caldas E. Cluster immunotherapy with glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment. Clin Exp Allergy 38 (2008) 987-994
26. Keskin O., Tuncer A., Adalioglu G., Sekerel B.E., Sackesen C., and Kalayci O. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr Allergy Immunol 17 (2006) 396-407
27. Klimek L., Mewes T., Wolf H., Hansen I., Schnitker J., and Mann W.J. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity. Otolaryngol Head Neck Surg 133 (2005) 538-543
28. Connell J.T., and Sherman W. Quantitative intranasal pollen challenges, III: the priming effect in allergic rhinitis. J Allergy 43 (1969) 33-44
29. Doyle W., Skoner D., Tanner E., and Fireman P. Lack of nasal priming after experimental ragweed challenge. J Allergy Clin Immunol 93 no. 1, part 2 (1994) 236
30. Frew A.J., White P.J., and Smith H.E. Sublingual immunotherapy. J Allergy Clin Immunol 104 (1999) 257-270
31. Canonica G.W., Baena-Cagnani C.E., Bousquet J., Bousquet P.J., Lockey R.F., Malling H.-J., et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: a statement of a World Allergy Organization (WAO) taskforce. Allergy 62 (2007) 317-324
32. Bordignon V., and Burastero S.E. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 97 (2006) 158-163
33. Calderon M.A., Alves B., Jacobson M., Hurwitz B., Sheikh A., and Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 1 (2007) CD001936
34. Di Rienzo V., Marcucci F., Puccinelli P., Parmiani S., Frati F., Sensi L., et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 33 (2003) 206-210
35. Wilson D.R., Torres Lima M., and Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60 (2005) 4-12